Objective    To observe the effect of atorvastatin on intraabdominal fat and microalbuminuria (MAU) in patients with metabolic syndrome (MS).     Methods    Forty-four MS patients were divided into the atorvastatin group and the control group. Blood pressure and blood glucose were controlled in both groups

in addition

atorvastatin was administered to the patients in the atorvastatin group. Blood pressure

blood glucose

body weight

abdominal wall fat

intraabdominal fat and MAU were compared before and after 12 weeks’ treatment.     Results    Obvious decrease of the intraabdominal fat and MAU was found in the atorvastatin group compared with those before the treatment [Intraabdominal fat: non-ACE1/ARB (41.76±3.61) mm vs (33.23±2.47) mm

P0.01; ACEI/ARB：（42.86±3.49）mm vs (30.49±2.87)mm

P0.01; MAU: (77.59±20.90) mg/24 h vs (35.20±14.45) mg/24 h; ACEI/ARB：（78.39±19.78）mg/24 h vs (32.91±13.87) mg/24 h

  P0.05]. Binary logistic regression analysis showed fasting glucose

TG

SBP

age and intraabdominal fat were independent risk factors of MAU.     Conclusion    Atorvastatin could decrease the intraabdominal fat and protect against renal lesion.